Orbimed Advisors Trims $125 After Breakout Year in Biotech
A major biotech stake shift signals evolving risk appetite. We break down the $125 million trim by ORBIMED Advisors, ...
Determine which funds deliver the best annual risk-adjusted returns and how they stack up. Compare contenders to pick winners.
28,456 articlesA major biotech stake shift signals evolving risk appetite. We break down the $125 million trim by ORBIMED Advisors, ...
OpenAI pursues a bold $1 trillion valuation as investors weigh hype against real-world profitability and a widening l...
DTI's 2025 earnings narrative sheds light on demand for drilling tools and oilfield equipment. This guide breaks down...
Powell’s newest remarks could mark a turning point for markets. This in-depth guide explains what a final warning mig...
Gen Z faces inflation, student debt, and a stubborn job market, pushing many to prioritize present spending over long...
A viral AI clip can shake trust in media and money alike. This article breaks down what happened, why it matters for ...
This summer, upgrade your investing skills with a practical summer reading list. Explore behavioral psychology, marke...
The U.S.-led airstrike on Iran sent markets into a tailspin, with oil surging and stock indexes dropping. As policyma...
Retirees are quietly piling into IDV, the iShares International Select Dividend ETF, chasing steady income and intern...
When markets hit new highs, Berkshire Hathaway's leaders offer a different playbook. Learn how Warren Buffett's Greg ...
Celebrity divorce headlines often hinge on money and math. This article breaks down the spousal support dispute aroun...
A bold move by Oracle in the AI data-center space could reshape demand for NVIDIA GPUs. This article explains what th...